Views 729
Citations 0
From The Medical Letter on Drugs and Therapeutics
April 21, 2015

MiniMed 530G: An Insulin Pump With Low-Glucose Suspend Automation

Author Affiliations

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2015;313(15):1568. doi:10.1001/jama.2015.2917

The FDA has approved the MiniMed 530G (Medtronic), an insulin pump used in combination with a continuous glucose monitoring sensor (Enlite) that can stop delivery of insulin when interstitial glucose reaches a prespecified low level. It is the only sensor-augmented insulin pump available in the US with this capability.

The MiniMed 530G system is approved in the US for patients ≥16 years old. It has been available in Europe as the Paradigm Veo since 2009. When interstitial glucose reaches a preset low-glucose threshold, an alert sounds and the pump automatically stops insulin delivery. After 2 hours, the insulin infusion starts again automatically, but the patient can override the suspension and restart insulin delivery at any time. The MiniMed 530G system, including the Enlite sensor and threshold suspend feature, costs about $7000, according to the manufacturer.

First Page Preview View Large
First page PDF preview
First page PDF preview